Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis

Journal of Nephrology

Volumn 31, Issue 3, 2018, Pages 321-332

  Amato, Laura ^a   Addis, Antonio ^a   Saulle, Rosella ^a   Trotta, Francesco ^a   Mitrova, Zuzana ^a   Davoli, Marina ^a  

^a DEPARTMENT OF EPIDEMIOLOGY   (Italy)

Author keywords

Anemia; Biosimilar; Chronic kidney disease; Efficacy; Epoetin; Erythropoiesis stimulating agents; Safety; Systematic review

Indexed keywords

ANTIANEMIC AGENT; BIOSIMILAR AGENT; RECOMBINANT ERYTHROPOIETIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; MACROGOL; RECOMBINANT PROTEIN;

BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPARATIVE EFFECTIVENESS; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HEMODIALYSIS; HUMAN; META ANALYSIS; MORTALITY; PERITONEAL DIALYSIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADULT; ANEMIA; COMPARATIVE STUDY; COMPLICATION;

ADULT; ANEMIA; BIOSIMILAR PHARMACEUTICALS; BLOOD TRANSFUSION; COMPARATIVE EFFECTIVENESS RESEARCH; DARBEPOETIN ALFA; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85034639042     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-017-0419-5     Document Type: Review

References (64)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316(2):73–78. doi:10.1056/nejm198701083160203 (Epub 1987/01/08)
2. Fishbane S (2009) Anemia in chronic kidney disease: status of new therapies. Curr Opin Nephrol Hypertens 18(2):112–115. doi:10.1097/MNH.0b013e328324b672 (Epub 2009/05/13)
3. Macdougall IC, Ashenden M (2009) Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 16(2):117–130. doi:10.1053/j.ackd.2008.12.010 (Epub 2009/02/24)
4. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD (1990) Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. BMJ 300(6725):655–659 (Epub 1990/03/10)
5. Fishbane S, Shah HH (2015) The emerging role of biosimilar epoetins in nephrology in the United States. Am J Kidney Dis Off J Natl Kidney Found 65(4):537–542. doi:10.1053/j.ajkd.2014.11.018 (Epub 2015/01/15)
6. Group IGOKAW. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Inter Suppl (2):279–335
7. Rompas S, Goss T, Amanuel S, Coutinho V, Lai Z, Antonini P et al (2015) Demonstrating value for biosimilars: a conceptual framework. Am Health Drug Benefits 8(3):129
8. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M et al (2014) Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 12:CD010590. doi:10.1002/14651858.CD010590.pub2 (Epub 2014/12/09)
9. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C et al (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7:10. doi:10.1186/1471-2288-7-10 (Epub 2007/02/17)
10. Higgins JP, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://www.cochrane-handbook.org
11. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. doi:10.1136/bmj.328.7454.1490 (Epub 2004/06/19)
12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–6. doi:10.1136/bmj.39489.470347.AD (Epub 2008/04/26)
13. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383–394. doi:10.1016/j.jclinepi.2010.04.026 (Epub 2011/01/05)
14. Schunemann HJ, Fretheim A, Oxman AD (2006) Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst BioMed Central 4:21. doi:10.1186/1478-4505-4-21 (Epub 2006/12/07)
15. Review Manager (RevMan) [Computer program] (2014) Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen
16. Alsalimy N, Awaisu A (2014) Methoxy polyethylene glycol-epoetin ß vs. darbepoetin α for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm 36(6):1115–1125. doi:10.1007/s11096-014-0023-x (Epub 2014/10/08)
17. Cases A, Portoles J, Calls J, Martinez-Castelao A, Munar MA, Segarra A (2014) Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA study. Int Urol Nephrol 46(10):1983–1995. doi:10.1007/s11255-014-0800-4 (Epub 2014/08/15)
18. Covic A, Nistor I, Donciu MD, Dumea R, Bolignano D, Goldsmith D (2014) Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies. Am J Nephro 40(3):263–279. doi:10.1159/000366025 (Epub 2014/10/18)
19. Hahn D, Cody JD, Hodson EM (2014) Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 5:CD003895. doi:10.1002/14651858.CD003895.pub3 (Epub 2014/05/30)
20. Harzallah A, Zouaghi K, Dridi A, Boubaker K, Beji S, Ayari M et al (2015) Therapeutic efficacy of a biosimilar epoetin α in hemodialysis patients. Saudi J Kidney Dis Transpl Off Publ Saudi Center Organ Transpl Saudi Arabia 26(1):78–82
21. Imai E, Maruyama S, Nangaku M, Hirakata H, Hayashi T, Narita I et al (2015) Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin α on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol
22. Locatelli F, Francisco A, Deray G, Fliser D, Armstrong G, Dougherty FC et al (2014) Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron–Clin Pract [Internet]. 128:323–32. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/728/CN-01052728/frame.html
23. Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF (2014) Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 3:CD009297. doi:10.1002/14651858.CD009297.pub2 (Epub 2014/04/01)
24. Sabbatini M, Vitale S, Garofalo G, Torino M, Gallo R, Carrano R et al (2014) Efficacy of subcutaneous epoetin-zeta on anemia in renal transplant recipients: a single-center experience. Transpl Proc 46(7):2238–2240
25. Tsubakihara Y, Akizawa T, Iwasaki M, Shimazaki R (2015) High hemoglobin levels maintained by an erythropoiesis-stimulating agent improve renal survival in patients with severe renal impairment. Therapeutic Apheresis Dial
26. Wilhelm-Leen ER, Winkelmayer WC (2015) Mortality risk of darbepoetin α vs. epoetin α in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis
27. Jehle PM, Jentzsch M, Langer T, Frohling P, Fiedler R (2014) Prospective 2-years study to evaluate malnutrition-inflammation- atherosclerosis (MIA) syndrome in hemodialysis patients: Inflammation-associated malnutrition is a significant predictor of mortality. [German]. Nieren- und Hochdruckkrankheiten [Internet] 43(4):167–176. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/687/CN-01001687/frame.html
28. Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K et al (2015) Comparison of pain and efficacy of darbepoetin α and epoetin ß pegol treatment in patients receiving peritoneal dialysis. J Nippon Med School [Internet] 82(1):21–26. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/065/CN-01069065/frame.html; https://www.jstage.jst.go.jp/article/jnms/82/1/82_21/_pdf
29. Beiraghdar F, Panahi Y, Einollahi B, Nemati E, Sahebkar A, Hassanzadeh A et al (2015) Evaluation of a biosimilar recombinant α epoetin in the management of anemia in hemodialysis patients. Saudi Pharm J
30. Goh BL, Ong LM, Sivanandam S, Lim TO, Morad Z, Biogeneric Epo Study Group (2007) Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Nephrology 12(5):431–436
31. Haag-Weber M, Vetter A, Thyroff-Friesinger U, Inj-Study Group (2009) Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72(5):380–390
32. Haag-Weber M, Eckardt KU, Horl WH, Roger SD, Vetter A, Roth K (2012) Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 77(1):8–17
33. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R et al (2008) Comparison of the therapeutic effects of epoetin zeta and epoetin α in the correction of renal anaemia. Curr Med Res Opin 24(5):1407–1415
34. Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M et al (2010) Therapeutic equivalence of epoetin zeta and α, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 27(2):105–117
35. Martin KJ, Epoetin Delta Study Group (2007) Epoetin delta in the management of renal anaemia: results of a 6-month study. Nephrol Dial Transpl 22(10):3052–3054
36. Milutinovic S, Plavljani E, Trkulja V (2006) Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. Fund Clin Pharmacol 20(5):493–502
37. Picon PD, Pribbernow SC, Prompt CA, Schacher SC, Antunes VV, Mentz BP et al (2014) Randomized double-blind clinical trial of a new human epoetin vs. a commercially available formula for anemia control in patients on hemodialysis. Clinics 69(8):547–553 (Epub 2014/08/21)
38. Spinowitz BS, Pratt RD (2006) Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 22(12):2507–2513. doi:10.1185/030079906x158048 (Epub 2006/12/15)
39. Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Saito A et al (2011) Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apheresis Dial 15(5):431–440
40. Al-Ali FS, El-Sayed Abdelfattah M, Fawzy AA, Hamdy AF, Abdulla AE (2015) Erythropoietin-stimulating agents in the management of anemia of end-stage renal disease patients on regular hemodialysis: a prospective randomized comparative study from Qatar. Hemodial Int 19(1):33–43. doi:10.1111/hdi.12181
41. Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K et al (2002) Pharmacokinetics and pharmacodynamics of darbepoetin α and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 72(5):546–555
42. Coyne D, Zeig R, Benz R, Berns J, Varma N, Nakanishi A et al (2006) A randomized, double-blind study comparing darbepoetin α and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in African-American (AA) subjects with chronic kidney disease (CKD) receiving hemodialysis (HD) [abstract no: TH-PO365]. J Am Soc Nephrol 17(Abstracts):184A-A
43. Hirakata H, Tsubakihara Y, Gejyo F, Nishi S, Iino Y, Watanabe Y et al (2010) Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. Clin Exp Nephrol 14(1):28–35
44. Hori K, Tsujimoto Y, Ohmori H, Nakamura H, Suga A, Iwasaki M et al (2004) Randomized, double-blind, comparative study of intravenous KRN321 (darbepoetin α) compared to intravenous recombinant human erythropoietin (rHuEPO) for treatment of anemia in subjects with chronic renal failure (CRF) receiving hemodialysis in Japan [abstract no: F-PO502]. J Am Soc Nephrol 15(Oct):177A-A
45. Li WY, Chu TS, Huang JW, Wu MS, Wu KD (2008) Randomized study of darbepoetin α and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Taiwan yi zhi=J Formos Med Assoc 107(11):843–850
46. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C et al (2001) Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60(2):741–747
47. Na HY, Lee YK, Shin SK, Yang DH, Cheon W, Park JH et al (2014) A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis. Kidney Res Clin Pract [Internet] 33(4):210–216. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/625/CN-01040625/frame.html; http://www.krcp-ksn.com/article/S2211-9132(14)00125-9/pdf
48. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C et al (2002) Randomized, controlled trial of darbepoetin α for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40(1):110–118
49. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T et al (2007) Efficacy of intravenous methoxy polyethylene glycol-epoetin ß administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 50(6):989–1000
50. Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S (2014) Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Ther Apheresis Dial Off Peer-Rev J Int Soc Apheresis Jpn Soc Apheresis Jpn Soc Dial Ther 18(5):421–6. doi:10.1111/1744-9987.12161 (Epub 2014/01/25)
51. Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ et al (2014) Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci 29(1):76–83. doi:10.3346/jkms.2014.29.1.76 (Epub 2014/01/17)
52. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC et al (2008) C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol CJASN 3(2):337–347
53. Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R et al (2011) C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transpl 26(12):3980–3986
54. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B et al (2010) Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin ß vs. darbepoetin α administered monthly: a randomized comparative trial. Nephrol Dial Transpl 25(12):4009–4017
55. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F et al (2008) Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin α: results from STRIATA, a randomized phase III study. Nephrol Dial Transpl 23(11):3654–3661
56. Campistol JM, Carreno A, Morales JM, Pallardo L, Franco A, Navarro D et al (2013) Once-monthly pegylated epoetin ß vs. darbepoetin α every two weeks in renal transplant recipients: a randomized trial. Transplantation 95(2):e6–e10
57. Tolman C, Richardson D, Bartlett C, Will E (2005) Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 16(5):1463–1470
58. Gertz B, Kes P, Essaian A, Bias P, Buchner A, Zellner D (2012) Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin ß. Curr Med Res Opin 28(7):1101–1110
59. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX et al (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153(1):23–33. doi:10.7326/0003-4819-153-1-201007060-00252 (Epub 2010/05/05)
60. Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369(9559):381–388. doi:10.1016/s0140-6736(07)60194-9 (Epub 2007/02/06)
61. Strippoli GF, Navaneethan SD, Craig JC (2006) Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 4:Cd003967. doi:10.1002/14651858.CD003967.pub2 (Epub 2006/10/21)
62. Marin JG, Leung M, Lo C, Tsao NW, Martinusen DJ (2014) Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review. Can J Kidney Health Dis 1:34. doi:10.1186/s40697-014-0034-5 (eCollection 2014)
63. Monaco A, Mammarella F, Cangini A, Marini R, Marengoni A, Russo P et al (2015) Generic and biosilimilar medicines use and expenditure: a report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA). J Gener Med Bus J Gener Med Sector 1741134315618535
64. Biosimilar report (2017)The impact of biosimilar competition in Europe IMS Quitiles May 2017. https://ec.europa.eu/docsroom/documents/23102/attachments/1/translations/en/renditions/native